Terms: = Breast cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
95 results:
1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of complexity and deliverability of IMRT treatment plans for breast cancer.
Duan L; Qi W; Chen Y; Cao L; Chen J; Zhang Y; Xu C
Sci Rep; 2023 Dec; 13(1):21474. PubMed ID: 38052915
[TBL] [Abstract] [Full Text] [Related]
3. treatment of Internal Mammary Nodes is Associated With Improved Overall Survival in breast cancer: A Meta-Analysis.
Shaikh PM; Mulherkar R; Khasawneh MT; Clump D; Hazard-Jenkins H; Hafez M; Vargo JA
Am J Clin Oncol; 2024 Feb; 47(2):81-87. PubMed ID: 37916961
[TBL] [Abstract] [Full Text] [Related]
4. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
[TBL] [Abstract] [Full Text] [Related]
5. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract] [Full Text] [Related]
6. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
7. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
8. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): a randomised, open-label, multicentre, phase 3 trial.
André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
[TBL] [Abstract] [Full Text] [Related]
9. Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy.
Suzuki Y; Kaneko H; Tamura Y; Okada A; Michihata N; Jo T; Takeda N; Morita H; Fujiu K; Node K; Yasunaga H; Komuro I
Oncology; 2023; 101(6):358-361. PubMed ID: 36940681
[TBL] [Abstract] [Full Text] [Related]
10. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early breast cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract] [Full Text] [Related]
11. Trends in Survival and Surgical Methods in Patients Surgically Treated for Metastatic Spinal Tumors: 25-Year Experience in a Single Institution.
Park SJ; Park JS; Lee CS; Kang BJ; Jung CW
Clin Orthop Surg; 2023 Feb; 15(1):109-117. PubMed ID: 36778984
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of a Liquid Biopsy-breast cancer Methylation (LBx-bcm) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
Visvanathan K; Cope L; Fackler MJ; Considine M; Sokoll L; Carey LA; Forero-Torres A; Ingle JN; Lin NU; Nanda R; Storniolo AM; Tulac S; Venkatesan N; Wu NC; Marla S; Campbell S; Bates M; Umbricht CB; Wolff AC; Sukumar S
Clin Cancer Res; 2023 Feb; 29(4):784-790. PubMed ID: 36534524
[TBL] [Abstract] [Full Text] [Related]
13. Side Bioimpedance Analysis in Menopausal Post-Oncological breast cancer.
Bifolco G; Pinazzi A; Bini V; Stefani L
Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141601
[TBL] [Abstract] [Full Text] [Related]
14. Determining the Optimal Cut-Off Values of Serum E2 and FSH for Evaluating the Menopausal Status of breast cancer Patients in a Southern Chinese Population.
Yang L; Li R; Yu M; Huang F; Zeng J; Lu Y; Yang C
Dis Markers; 2022; 2022():8716160. PubMed ID: 36046380
[TBL] [Abstract] [Full Text] [Related]
15. Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer.
Fackler MJ; Tulac S; Venkatesan N; Aslam AJ; de Guzman TN; Mercado-Rodriguez C; Cope LM; Downs BM; Vali AH; Ding W; Lehman J; Denbow R; Reynolds J; Buckley ME; Visvanathan K; Umbricht CB; Wolff AC; Stearns V; Bates M; Lai EW; Sukumar S
Cancer Res Commun; 2022 Jun; 2(6):391-401. PubMed ID: 36046124
[TBL] [Abstract] [Full Text] [Related]
16. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract] [Full Text] [Related]
17. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract] [Full Text] [Related]
18. Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative breast cancer via Regulation of Epigenetic Mechanisms.
Sharma M; Arora I; Chen M; Wu H; Crowley MR; Tollefsbol TO; Li Y
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836197
[TBL] [Abstract] [Full Text] [Related]
19. Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
Jalloul N; Gomy I; Stokes S; Gusev A; Johnson BE; Lindeman NI; Macconaill L; Ganesan S; Garber JE; Khiabanian H
JCO Precis Oncol; 2021; 5():. PubMed ID: 34820595
[TBL] [Abstract] [Full Text] [Related]
20. Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.
O'Keefe TJ; Harismendy O; Wallace AM
Int J Clin Oncol; 2022 Jan; 27(1):121-130. PubMed ID: 34618239
[TBL] [Abstract] [Full Text] [Related]
[Next]
